Minimally invasive coronary artery bypass surgery: prospective and radomized study to validate the minimally invasive approach through left anterior mini thoracotomy in patients with Multi vessel coronary disease

• Grant number: 21/11947-5
• Support Opportunities: Regular Research Grants
• Start date: August 01, 2022
• End date: July 31, 2025
• Field of knowledge: Health Sciences - Medicine - Surgery
• Principal Investigator: Luiz Augusto Ferreira Lisboa
• Grantee: Luiz Augusto Ferreira Lisboa
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil
• Associated researchers: Fabio Biscegli Jatene ; Luis Alberto Oliveira Dallan ; Luis Roberto Palma Dallan ; Omar Asdrúbal Vilca Mejía

Abstract

Minimally invasive surgery has been a breakthrough in medicine, especially in more developed countries. It represents an evolution of current techniques associated with new technologic devices, that allow a safe and effective procedure associated to an aesthetic benefit. Invasive treatment of coronary artery disease has been on a plateau lately. Percutaneous treatment, that emerged as a promise to replace surgical methods, has already shown its limitations, even with the use of drug-eluting stents. Traditional CABG (coronary artery bypass grafting surgery), which has been considered the gold standard, has been criticized for its high degree of invasiveness. Based on this precept, interest has emerged in creating a surgical approach that causes less trauma. Surgical access using minimally invasive incisions are gaining space and have shown less postoperative pain, shorter hospital stays, earlier mobilization and functional recovery, in addition to reducing the costs of the procedure. Based on the minimally invasive approach, we designed a Prospective, randomized, unblinded, single center trial of 100 patients. Following diagnostic angiography demonstrating significant triple-vessel coronary disease and surgeon's consensus of the feasibility to perform both surgical approaches and that the patient meets all the study entry criteria, patients will be consented and randomized 1:1 to: a) Minimally Invasive Coronary Artery Bypass surgery, or b) conventional coronary artery bypass surgery (CABG). Follow-up for all randomized patients will continue for a minimum of 6 months. (AU)